Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Telmisartan combined with hydrochlorothiazide

First Posted Date: 2014-09-17

Last Posted Date: 2014-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3320

Registration Number: NCT02242877

Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Placebo-MDI
Drug: Placebo HandiHaler®
Drug: Salmeterol

First Posted Date: 2014-09-17

Last Posted Date: 2014-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 97

Registration Number: NCT02242253

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium medium dose
Drug: Tiotropium low dose
Drug: Spiriva® HandiHaler® high dose
Drug: Placebo via the grey HandiHaler®
Drug: Placebo via the blue HandiHaler®

First Posted Date: 2014-09-17

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 121

Registration Number: NCT02242266

Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: MicardisPlus®

First Posted Date: 2014-09-17

Last Posted Date: 2014-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8148

Registration Number: NCT02242825

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: Micardis® Plus

First Posted Date: 2014-09-17

Last Posted Date: 2014-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14553

Registration Number: NCT02242357

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran etexilate
Drug: Vitamin K antagonists

First Posted Date: 2014-09-16

Last Posted Date: 2019-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1506

Registration Number: NCT02240667

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Procedure: Best Supportive Care
Drug: BI 836858

First Posted Date: 2014-09-16

Last Posted Date: 2020-12-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02240706

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇩🇪
Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States

and more 2 locations

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2014-09-16

Last Posted Date: 2018-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 128

Registration Number: NCT02240693

Locations: 🇩🇪
emovis GmbH, Berlin, Germany
🇫🇷
HOP Jean Bernard, Géria, Poitiers, Poitiers, France
🇩🇪
Praxis Dr. med. Volker Schumann, Berlin, Germany

and more 49 locations

Linagliptin as Add on to Basal Insulin in the Elderly

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: linagliptin

First Posted Date: 2014-09-16

Last Posted Date: 2018-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT02240680

Locations: 🇯🇵
Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan
🇯🇵
Yoshida Memorial Hospital, Hokkaido, Sapporo, Japan
🇺🇸
East Coast Institute for Research LLC at NE FL Endo & Diabetes, Jacksonville, Florida, United States

and more 142 locations

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated

Conditions: Hypertension

Interventions: Drug: Lacidipine
Drug: Diuretics
Drug: antihypertensive drugs
Drug: alpha blockers
Drug: Angiotensin-Converting Enzyme Inhibitors
Drug: beta blockers

First Posted Date: 2014-09-16

Last Posted Date: 2014-09-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5417

Registration Number: NCT02240641

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy